Affibody’s discovery pipeline contains candidate binders for interesting targets (including CAIX, EGFR, HER2, HER3, PDGFRβ), available for out-licensing.

Therapy
Affibody has obtained promising pre-clinical data in its lead therapy program, where therapeutic efficacy has been demonstrated with two different payloads.

Imaging
A proprietary imaging agent has been demonstrated to successfully target metastases in humans. The lead imaging agent has been shown to be safe and non immunogenic in preclinical studie, and has been approved for a German breast cancer imaging study and a Swedish bladder cancer imaging study.